



ORIGINAL ARTICLE

Evaluation of dose–response relationship between smoking load and cardiopulmonary fitness in adult smokers: A cross-sectional study



V.T. Lauria^{a,*}, E.F. Sperandio^a, T.L.W. de Sousa^a, W. de Oliveira Vieira^a, M. Romiti^b, A.R. de Toledo Gagliardi^b, R.L. Arantes^b, V.Z. Dourado^a

^a Laboratory of Epidemiology and Human Movement (EPIMOV), Federal University of São Paulo, Santos, Brazil

^b Angiocorpore Institute of Cardiovascular Medicine, Santos, Brazil

Received 2 June 2016; accepted 22 November 2016

Available online 31 January 2017

KEYWORDS

Smoking load;
Cardiopulmonary
exercise testing;
Spirometry;
Physical fitness;
Tobacco use disorder

Abstract

Objective: To evaluate the dose–response relationship between smoking load and cardiopulmonary fitness, as measured with cardiopulmonary exercise testing (CPET), in adult smokers free of respiratory diseases.

Methods: After a complete clinical evaluation and spirometry, 95 adult smokers (35 men and 60 women) underwent CPET on a treadmill.

Results: The physiological responses during CPET showed lower cardiorespiratory fitness levels, regardless of smoking load, with a peak \dot{V}_{O_2} lower than 100% of the expected value and a lower maximum heart rate. We observed a significant moderate negative correlation between smoking load and peak \dot{V}_{O_2} . The smoking load also presented a significant negative correlation with maximum heart rate ($r = -0.36$; $p < 0.05$), lactate threshold ($r = -0.45$; $p < 0.05$), and peak ventilation ($r = -0.43$; $p < 0.05$). However, a dose–response relationship between smoking load quartiles and cardiopulmonary fitness was not found comparing quartiles of smoking loads after adjustment for age, sex and cardiovascular risk.

Conclusion: There appears to be no dose–response relationship between SL and cardiopulmonary fitness in adult smokers with preserved pulmonary function, after adjusting the analysis for age and cardiovascular risk. Our results suggest that smoking cessation might be useful as the primary strategy to prevent cardiopulmonary fitness decline in smokers, regardless of smoking load. Thus, even a very low dose of tobacco use must be avoided in preventive strategies focusing on becoming people more physically active and fit.

© 2016 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: viniciuslauria@hotmail.com (V.T. Lauria).

Introduction

Tobacco use continues to be the leading global cause of preventable deaths.¹ Smoking affects health among young smokers without established chronic disease.² Smoking increases the risk of developing respiratory and cardiovascular diseases, and it is responsible for causing many types of cancer, even in non-smokers exposed to second-hand tobacco smoke (SHS). When smoking, a person inhales an average of 2500 toxic substances leading to symptoms such as increased mucus production, airway inflammation, infections, and decreased muscular function.³

Smoking is associated not only with lower physical activity, but also with impaired cardiorespiratory fitness and heart rate variability.⁴ The best way to determine cardiorespiratory fitness is through cardiopulmonary exercise testing (CPET). One of the variables used to determine the functional cardiorespiratory capacity is the measurement of the pulmonary oxygen uptake (\dot{V}'_{O_2}) at peak exercise intensity.

Smoking load (SL), expressed in pack-years, is widely used as a simple way to quantify current tobacco use. An SL greater than 15 pack-years should have detailed screening for respiratory diseases, such as chronic obstructive pulmonary disease (COPD).⁵ Lung cancer screening is recommended for individuals with an SL greater than 30 pack-years.⁶ However, the health effects of lower SL are not fully understood. Although there is detailed knowledge of the negative effects of smoking, there are few studies on the dose-response relationship of SL and cardiorespiratory fitness. The objective of this study was to evaluate the dose-response relationship between SL and cardiopulmonary fitness through CEPT in adult smokers with preserved pulmonary function.

Methods

In this cross-sectional study, 95 adult smokers (35 men and 60 women) underwent CPET on a treadmill, after a complete clinical evaluation and spirometry. Participants were selected from the EPIMOV Study (Epidemiology and Human Movement Study). Briefly, the EPIMOV Study, is a cohort study with the main objective of investigating the longitudinal association between sedentary behavior and physical inactivity with the occurrence of hypokinetic diseases, especially cardiorespiratory diseases. The volunteers were recruited through dissemination in social networks, folders displayed in the universities of the region, local magazines and newspapers. Inclusion criteria for this study were male or female aged between 18 and 90 years and being free from self-reported physician-diagnosed cardiac or pulmonary disease. Exclusion criteria were orthopedic problems, recent respiratory infections, unstable or stable angina in the last four weeks, recent myocardial infarction, angioplasty or cardiac surgery in the last three months and spirometric abnormalities. We have excluded participants considering impaired functional vital capacity ($FVC < 80\%$ predicted) and/or low relationship between forced expiratory volume in the 1st second and FCV (FEV_1/FVC ratio ≤ 0.7 in absolute value).⁷⁻⁹ In order to calculate the predicted spirometric variables, Brazilian reference values¹⁰ were used. The participants were informed about the possible

risks and discomforts of the procedures proposed in the present study and signed a consent form. The Ethics Committee for Research in Humans of the local university approved this study by the 186.796 protocol.

Clinical evaluation

The height and weight of the subjects were measured and the body mass index (BMI) was calculated. Personal and demographic data were collected (e.g., sex, age, education, home address). In addition, participants answered the physical activity readiness questionnaire (PAR-Q) in order to evaluate some possible contraindication for CPET¹¹; questions about respiratory disorders based on the American Thoracic Society (ATS) questionnaire¹² to investigate pollutants exposition, history of asthma and smoking status; and cardiovascular disease (CVD) risk stratification was performed according to the American College of Sports Medicine (ACSM).¹³ We investigated the presence of self-reported major risk factors for CVD, including age (male ≥ 45 years; female ≥ 55 years); family history of premature coronary heart disease (CHD) (definite myocardial infarction before 55 years old in father or 65 years old in mother or other first-degree relative); systemic arterial hypertension; diabetes; dyslipidemia and current cigarette smoking.

Spirometry

The forced vital capacity (FVC) was determined using a calibrated spirometer (Quark PTF; COSMED, Pavnodi Albano, Italy), following the criteria of the American Thoracic Society (ATS).¹⁴ The forced expiratory volume in 1-s (FEV_1) was measured, and then the FEV_1/FVC ratio was calculated. All spirometric values were measured in absolute and percentage of normal values by using reference values for the Brazilian population.¹⁰

Cardiopulmonary exercise testing

All participants were informed about the preparatory procedures prior to CPET. Several recommendations were standardized, such as not smoking on the assessment day, not performing intense exercise on test day and avoiding coffee, tea or on test day. CPET was done on a treadmill (ATL, Inbrasport, Curitiba, Brasil) by using a ramp protocol. Pulmonary oxygen uptake (\dot{V}'_{O_2}), carbon dioxide output (\dot{V}'_{CO_2}) and minute ventilation (\dot{V}_E) were recorded using a computerized system for cardiopulmonary exercise testing, periodically calibrated following the manufacturer's recommendations (Quark PTF; COSMED, Pavona di Albano, Italy). Heart rate was monitored during CPET with a 12-lead EKG (C12x; COSMED, Pavona di Albano, Italy). The \dot{V}'_{O_2} equivalent to the lactate threshold was obtained through a gas exchange technique, visually inspecting the $\dot{V}_{CO_2}/\dot{V}'_{O_2}$ slope inflection point (v-slope) and by using the oxygen (\dot{V}_E/\dot{V}'_{O_2}) and carbon dioxide ($\dot{V}_E/\dot{V}'_{CO_2}$) ventilatory equivalents.¹⁵ The data were averaged every 15-s. The average of the last 15 s at the end of the test, immediately before the recovery phase, was considered the peak \dot{V}'_{O_2} . Subjects with less

than 83% of the predicted peak \dot{V}_{O_2} were considered exercise intolerant.¹⁶

Statistical analysis

The sample size was calculated assuming a minimum clinically significant difference of 442 mL/min in peak \dot{V}_{O_2} during the CPET in healthy individuals (i.e., the lower limit of normal).¹⁷ This was selected because the standard deviation of peak \dot{V}_{O_2} in healthy adults is about 400 mL/min.¹⁷ From this, the probability of alpha and beta errors was set at 0.05 and 0.20, respectively, establishing a minimum sample size of 17 participants in each of the quartiles for CPET to detect a 442 mL difference in peak \dot{V}_{O_2} . Thus, a sample size of 68 subjects was calculated in our study.

Data were analyzed and normal variables presented as the mean \pm standard deviation, or as median (interquartile range) for non-normal variables. The correlation between SL and the data obtained in the CPET were evaluated with the Pearson or Spearman correlation coefficient, according to the normality of the variables. The SL was retrospectively categorized into the 25th, 50th, and 75th percentiles. Peak \dot{V}_{O_2} was compared using multivariate analysis of variance (MANOVA) and adjusted for the following main confounding variables: age, sex, systemic arterial hypertension, diabetes mellitus, dyslipidemia, obesity, and physical inactivity. A p value <0.05 was considered significant.

Results

This study evaluated 95 smokers without pulmonary disease. The subjects were, on average, middle-aged, with a BMI indicating obesity and normal spirometry (Table 1). Restrictive impairment was present in 13 (13.7%) subjects. Cardiovascular risk factors were present: 13% were diabetic, 21% had systemic arterial hypertension, 28% had dyslipidemia, 46% were obese, and 69% were physically inactive.

In general, the physiological responses during the CPET represented a lower cardiorespiratory fitness level, as indicated by peak \dot{V}_{O_2} lower than 100% of the expected and a lower maximum heart rate (Table 1). Thirty-two subjects (33.6%) had exercise intolerance. A significant moderate negative correlation between SL and the peak \dot{V}_{O_2} was detected (Fig. 1). The SL also showed significant correlation with maximum heart rate ($r = -0.36$; $p < 0.05$), lactate threshold ($r = -0.45$; $p < 0.05$) and peak VE ($r = -0.43$; $p < 0.05$).

The SL quartiles were divided as ≤ 3 , between 3 and 12, between 12.1 and 32 and >32 pack-years. The participants with an SL greater than 32 pack-years were older and had a higher prevalence of dyslipidemia and physical inactivity (Table 2).

Despite the negative correlation between the SL and the peak \dot{V}_{O_2} , the peak \dot{V}_{O_2} values were not statistically different among the SL quartiles (Fig. 2) when adjusted for age, sex and risk factors for cardiovascular disease.

Discussion

In this study, we evaluated the influence of the SL on cardiopulmonary fitness in asymptomatic adult smokers and

Table 1 General characteristics of the study subjects and physiological responses observed in the cardiopulmonary exercise testing.

	Mean \pm SD
Age (years)	45 \pm 12
Weight (kg)	83 \pm 23
Sex (Male/Female)	35/60
Height (m)	1.63 \pm 0.08
BMI (Kg/m ²)	30.7 \pm 7.5
FVC (L)	3.32 \pm 3.03
FVC (% of predicted)	90.5 \pm 13.8
FEV ₁ (L)	2.68 \pm 0.91
FEV ₁ (% of predicted)	88.7 \pm 15.3
FEV ₁ /FVC (%)	80.0 \pm 7.4
Peak \dot{V}_{O_2} (mL/min)	2038 \pm 774
Peak \dot{V}_{O_2} (mL/min/Kg)	24 \pm 8
Peak \dot{V}_{O_2} (% of expected)	88 \pm 15
Anaerobic threshold (mL/min)	1376 \pm 505
Anaerobic threshold (% of the predicted peak \dot{V}_{O_2})	60 \pm 12
Rate of gas exchange ($\dot{V}_{CO_2}/\dot{V}_{O_2}$)	1.13 \pm 0.11
Maximum heart rate (bpm)	153 \pm 19
Maximum heart rate (% of predicted)	88 \pm 8
Maximum minute ventilation (L/min)	66 \pm 25

SD, standard deviation; BMI, body mass index; FVC, forced vital capacity; FEV₁, forced expiratory volume in the first second; \dot{V}_{O_2} , oxygen uptake; \dot{V}_{CO_2} , carbon.

observed negative correlations between these variables. Despite these negative correlations, no dose-response relationship between the SL and the cardiorespiratory fitness was demonstrated.





Figure 1 Significant correlations ($p < 0.05$) between smoking load and peak oxygen uptake at the end of cardiopulmonary exercise testing in women ($r = -0.26$; $R^2 = 0.06$) and men ($r = -0.36$; $R^2 = 0.12$). Overall, the correlation was moderate ($r = -0.32$; $R^2 = 0.10$).

Table 2 Demographic, anthropometric, and cardiovascular risk data in the study subjects, stratified according to the smoking load quartiles.

	Smoking load (pack-years)			
	Quartile 1 ≤3	Quartile 2 3–12	Quartile 3 12.1–32	Quartile 4 >32
Age (years)	40 ± 11	40 ± 12	48 ± 9	57 ± 9 ^{*,**,*}
Sex (Male/Female)	8/16	12/13	10/14	5/17
Weight (Kg)	88.7 ± 20.7	86.1 ± 24.4	85.1 ± 25.7	70.6 ± 18.3
Height (m)	1.65 ± 0.99	1.65 ± 0.91	1.64 ± 0.10	1.59 ± 0.97
BMI (Kg/m ²)	32.6 ± 7.6	31.2 ± 7.5	31.3 ± 8.4	27.5 ± 6
Arterial hypertension	25%	20%	20.8%	18.2%
Diabetes mellitus	12.5%	4%	8.3%	31.8%
Dyslipidemia	8.3%	20%	41.7%	45.5% [*]
Obesity	54.2%	40%	33.3%	40.9%
Physical inactivity	70.8%	52%	66.7%	90.0% ^{**}

BMI, body mass index.

^{*} $p < 0.05$ vs. Quartile 1.^{**} $p < 0.05$ vs. Quartile 2.^{***} $p < 0.05$ vs. Quartile 3.**Figure 2** Peak oxygen uptake at the end of cardiopulmonary exercise testing according to smoking load in pack-yr (quartile 1, ≤3; quartile 2, 3–12; quartile 3, 12.1–32; and quartile 4, >32). There were no significant differences among groups after multivariate analysis of variance adjusted by age, sex, arterial hypertension, diabetes, dyslipidemia, obesity, and physical inactivity.

We have also observed that the cardiopulmonary fitness as determined by the peak \dot{V}_{O_2} was 12% lower than the expected in all four of the SL quartiles we studied, and about one-third (33.6%) of the subjects were exercise intolerant. In fact, our results reinforce the current literature. Misigoj-Durakovic et al.¹⁸ evaluated 350 Croatian Armed Forces members, of which 175 were smokers and 175 were non-smokers. The smokers were classified into three groups according to their SL (group 1, from 1 to 5 pack-years; group 2, from 5 to 10; and group 3, over 10 pack-years), and the

non-smokers in three control groups. Cardiopulmonary fitness by treadmill CPET showed a significant reduction in the peak \dot{V}_{O_2} , even in smokers with an SL lower than five pack-years. As far as we know, very few studies have evaluated the negative effects of very low SL. As with the Croatian study, our results show that smoking has a negative effect on cardiopulmonary fitness in a non-dose dependent manner. The effect persisted at very low SLs even though the \dot{V}_{O_2} was dose dependent and peaked, at an SL above three pack-years.

We showed that greater reductions in cardiopulmonary fitness in smokers with a higher SL are associated with age, dyslipidemia, and physical inactivity. According to Malta et al.,¹⁹ the frequency of intense smoking has a tendency to increase with age, increasing more than two fold between 18–24 and 55–64 years. Likewise, the cardiopulmonary and muscular fitness decreases as the individual ages.¹⁸ Smoking is also related to other cardiovascular risk factors. Studies have shown that heavy smokers present more comorbidities in comparison to light smokers.²⁰ Heavy smokers have lower values in diffusing capacity, which explains the reduction in maximum exercise capacity.²¹ Nevertheless, it is possible that observational associations between heavy smoking and cardiovascular risks can be misinterpreted, since heavy smoking is related to sedentary behavior, clinical conditions and socioeconomic factors that cannot be entirely eliminated as potential confounders.²² Furlanetto et al.²³ studied the level of physical activity in the daily life of 116 subjects, smokers and non-smokers, using a pedometer. The results have shown a significant reduction in the daily physical activity levels in adult smokers despite the absence of obstructive pulmonary disease. However, comparing the SL quartiles in our study, we found no difference in the negative effects of smoking in cardiopulmonary fitness on comparing subjects with an SL of 3 pack-years and subjects with an SL of more than 32 pack-years.

The SL did have a negative correlation with the main variables of the cardiopulmonary fitness in the CPET. The

maximum heart rate showed very low average values (88% of the expected) despite the fact that the values for respiratory exchange ratio were compatible with maximum effort. A lower maximum heart rate in smokers during CPET was also observed by Unverdorben et al.²⁴ Smoking alters the chronotropic response to exercise, increasing the risk of developing coronary artery disease and death.²⁵ This deleterious effect on chronotropic response to exercise can lead to compromised cardiac output, to a reduction in transcutaneous oxygen tension, to a reduction in the anaerobic threshold, and to an increase in catecholamine release.²⁶ In fact, a significant reduction in the peak \dot{V}_{O_2} was even observed in SHS.²⁵

Despite a reduction by 12% in the expected peak \dot{V}_{O_2} , the subjects of this study presented a normal anaerobic threshold (about 60% of the expected peak \dot{V}_{O_2}). In contrast to our results, Glaser et al.²⁷ observed a significant reduction in the anaerobic threshold in smokers compared to non-smokers. However, physical inactivity affects the values of \dot{V}_{O_2} and the anaerobic threshold, a confounder, which was not considered. It is well known that smokers present higher $\dot{V}E/\dot{V}_{CO_2}$ ratios and a lower anaerobic threshold.²⁷ This shows a reduction in ventilatory efficiency and certainly contributes to the overall reduction in the exercise capacity at higher but not at lower exercise intensity.

Some limitations of our study must be considered. Despite the correlations observed in the study, the cross-sectional design did not allow us to establish any relationship of cause and effect. We did not evaluate a control group of non-smokers, which might have changed the interpretation of the data. However, the predicted \dot{V}_{O_2} values show that exercise capacity was clearly below normal. The convenient selection and the low sample size may have led us into an external validity issue regarding the SL sub-groups, and could explain the higher prevalence of comorbidities than in the general population. The lack of an objective control over the last cigarette smoked before CPET is another limitation of the present study. Smoking can cause acute effects in physiological responses to the CPET. However, all the CPETs were performed in the same cardiovascular clinic and the clinic staff carefully advised our participants about avoiding exercise and smoking before the CPET. For this reason, we are confident we have been able to minimize this bias. Additionally, we did not evaluate the level of nicotine dependence. We recognize that this could be of great value since there are very few studies on the correlation of nicotine dependence and cardiopulmonary fitness. We should also state that the self-reported evaluations are subjective.

Conclusion

Based on our findings, after adjusting the analysis for age and cardiovascular risk, there appears to be no dose-response relationship between SL and cardiopulmonary fitness in adult smokers with preserved pulmonary function. Therefore, smoking cessation might be useful as the primary strategy to prevent cardiopulmonary fitness decline in smokers, regardless of smoking load. Thus, even a very low dose of tobacco use must be avoided in preventive strategies.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflict of interest

The authors have no conflicts of interest to declare.

Funding

This study received financial support in the form of a research grant from the São Paulo Research Foundation (FAPESP), in the State of São Paulo, Brazil, grant no. 2011/07282-6.

References

1. Organization WH. WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. Geneva: World Health Organization; 2011.
2. Celermajor DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. *Circulation*. 1993;88 Pt 1:2149–55 [Epub 1993/11/01].
3. Zanoni CT, Rodrigues CMC, Mariano D, Suzan A, Boaventura LC, Galvão F. Efeitos do treinamento muscular inspiratório em universitários tabagistas e não tabagistas. *Inspiratory muscle training effects in smokers and nonsmokers university students. Fisioter Pesqui*. 2012;19:147–52.
4. Lee CL, Chang WD. The effects of cigarette smoking on aerobic and anaerobic capacity and heart rate variability among female university students. *Int J Womens Health*. 2013;5:667–79 [Epub 2013/11/10].
5. Pereira CAC, Neder JA. Diretrizes para testes de função pulmonar. *J Bras Pneumol*. 2002;28 Suppl. 3:S1–238.
6. Lowry KP, Gazelle GS, Gilmore ME, Johanson C, Munshi V, Choi SE, et al. Personalizing annual lung cancer screening for patients with chronic obstructive pulmonary disease: a decision analysis. *Cancer*. 2015;121:1556–62 [Epub 2015/02/06].
7. Eriksson B, Lindberg A, Mullerova H, Ronmark E, Lundback B. Association of heart diseases with COPD and restrictive lung function – results from a population survey. *Respir Med*. 2013;107:98–106 [Epub 2012/11/07].
8. Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. *Am J Med*. 2003;114:758–62 [Epub 2003/06/28].
9. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on

- spirometry: findings from the First National Health and Nutrition Examination Survey and follow-up. *Int J Tuberc Lung Dis*. 2005;9:613–21 [Epub 2005/06/24].
10. Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. *J Bras Pneumol*. 2007;33:397–406 [Epub 2007/11/06].
 11. Thomas S, Reading J, Shephard RJ. Revision of the physical activity readiness questionnaire (PAR-Q). *Can J Sport Sci*. 1992;17:338–45 [Epub 1992/12/01].
 12. Ferris BG. Epidemiology standardization project (American Thoracic Society). *Am Rev Respir Dis*. 1978;118 Pt 2:1–120 [Epub 1978/12/01].
 13. Thompson PD, Arena R, Riebe D, Pescatello LS. ACSM's new preparticipation health screening recommendations from ACSM's guidelines for exercise testing and prescription, ninth edition. *Curr Sports Med Rep*. 2013;12:215–7 [Epub 2013/07/16].
 14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J*. 2005;26:319–38 [Epub 2005/08/02].
 15. Wasserman K, Hansen J, Sue DY, Whipp BJ, Casaburi R. Principles of exercise testing and interpretation. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005, 576 p.
 16. Neder JA, Nery LE, Shinzato GT, Andrade MS, Peres C, Silva AC. Reference values for concentric knee isokinetic strength and power in nonathletic men and women from 20 to 80 years old. *J Orthop Sports Phys Ther*. 1999;29:116–26.
 17. Neder JA, Nery LE, Castelo A, Andreoni S, Lerario MC, Sachs A, et al. Prediction of metabolic and cardiopulmonary responses to maximum cycle ergometry: a randomised study. *Eur Respir J*. 1999;14:1304–13 [Epub 2000/01/07].
 18. Misigoj-Durakovic M, Bok D, Soric M, Dizdar D, Durakovic Z, Jukic I. The effect of cigarette smoking history on muscular and cardiorespiratory endurance. *J Addict Dis*. 2012;31:389–96 [Epub 2012/12/19].
 19. Malta DC, Moura EC, Silva SA, Oliveira PPVd, Silva VLdCe. Prevalência do tabagismo em adultos residentes nas capitais dos estados e no Distrito Federal, Brasil, 2008. *J Bras Pneumol*. 2010;36:75–83.
 20. Asvold BO, Bjorngaard JH, Carslake D, Gabrielsen ME, Skorpen F, Smith GD, et al. Causal associations of tobacco smoking with cardiovascular risk factors: a Mendelian randomization analysis of the HUNT Study in Norway. *Int J Epidemiol*. 2014;43:1458–70 [Epub 2014/05/29].
 21. Tzani P, Aiello M, Colella M, Verduri A, Marangio E, Olivieri D, et al. Lung diffusion capacity can predict maximal exercise in apparently healthy heavy smokers. *J Sports Sci Med*. 2008;7:229.
 22. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2007;298:2654–64 [Epub 2007/12/13].
 23. Furlanetto KC, Mantoani LC, Bisca G, Morita AA, Zabatiero J, Proenca M, et al. Reduction of physical activity in daily life and its determinants in smokers without airflow obstruction. *Respirology*. 2014;19:369–75 [Epub 2014/02/04].
 24. Unverdorben M, van der Bijl A, Potgieter L, Venter C, Munjal S, Qiwei L, et al. Effects of different levels of cigarette smoke exposure on prognostic heart rate and rate – pressure-product parameters. *J Cardiovasc Pharmacol Ther*. 2008;13:175–82 [Epub 2008/07/17].
 25. de Borja AT, Jost RT, Gass R, Nedel FB, Cardoso DM, Pohl HH, et al. The influence of active and passive smoking on the cardiorespiratory fitness of adults. *Multidiscip Respir Med*. 2014;9:34 [Epub 2014/07/11].
 26. Unverdorben M, der Bijl A, Potgieter L, Liang Q, Meyer BH, Roethig HJ. Effects of levels of cigarette smoke exposure on symptom-limited spiroergometry. *Prev Cardiol*. 2007;10:83–91 [Epub 2007/03/31].
 27. Glaser S, Koch B, Ittermann T, Schaper C, Dorr M, Felix SB, et al. Influence of age, sex, body size, smoking, and beta blockade on key gas exchange exercise parameters in an adult population. *Eur J Cardiovasc Prev Rehabil*. 2010;17:469–76 [Epub 2010/03/23].